INVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in Replimune Group, Inc. of Class Action Lawsuit and Upcoming Deadlines – REPL

Pomerantz Law Firm has filed a class action lawsuit against Replimune Group, Inc. following the FDA's rejection of the company's Biologics License Application for RP1 in combination with nivolumab on April 10, 2026. The FDA cited deficiencies in clinical studies and stated the evidence did not meet approval standards. The stock price fell 19.46% on the announcement and an additional 64.29% days later, totaling an 83.75% decline from $4.76 to $1.70 per share. Investors who purchased securities during the class period have until October 5, 2026, to request Lead Plaintiff status.